The increased difficulty in carrying out clinical research studies in academic medical centers is a problem of great concern. As noted by Drs Yaar and Gilchrest, the stringent regulations of the Food and Drug Administration and their strict enforcement preclude initiating many new research projects as well as employing emerging innovative therapies.
Arndt KA. Editorial Footnote. Arch Dermatol. 2001;137(3):349. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-137-3-ded0349